[{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Allysta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ALY688","moa":"Adiponectin receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Allysta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allysta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Allysta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Allysta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"ALY688","moa":"Adiponectin receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Allysta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allysta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Allysta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Allysta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ALY688","moa":"Adiponectin receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Allysta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allysta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Allysta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Allysta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ALY688","moa":"Adiponectin receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Allysta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allysta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Allysta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InflammX Therapeutics","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Tonabersat","moa":"anticonvulsants","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"InflammX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InflammX Therapeutics \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"9","companyTruncated":"InflammX Therapeutics \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Jason Ahee, M.D.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Moxifloxacin","moa":"Bacterial DNA gyrase","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Jason Ahee, M.D.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jason Ahee, M.D. \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jason Ahee, M.D. \/ Undisclosed"},{"orgOrder":0,"company":"Quark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Oligonucleotide","year":"2015","type":"Inapplicable","leadProduct":"QPI-1007","moa":"Caspase 2 messenger RNA (CASP2 mRNA)","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Quark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Quark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Quark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2019","type":"Inapplicable","leadProduct":"Sepofarsen","moa":"CEP290 mRNA","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProQR Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Sepofarsen","moa":"CEP290 mRNA","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProQR Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AVD-104","moa":"Complement pathway","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aviceda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aviceda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Aviceda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AVD-104","moa":"Complement pathway","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aviceda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aviceda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Aviceda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AVD-104","moa":"Complement pathway","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aviceda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aviceda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Aviceda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AVD-104","moa":"Complement pathway","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aviceda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aviceda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Aviceda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series C Financing","leadProduct":"AVD-104","moa":"Complement pathway","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aviceda Therapeutics","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.20999999999999999,"dosageForm":"Injection","sponsorNew":"Aviceda Therapeutics \/ Omega Funds","highestDevelopmentStatusID":"9","companyTruncated":"Aviceda Therapeutics \/ Omega Funds"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AVD-104","moa":"Complement pathway","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aviceda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aviceda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Aviceda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AVD-104","moa":"Complement pathway","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aviceda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aviceda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Aviceda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AVD-104","moa":"Complement pathway","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aviceda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aviceda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Aviceda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AVD-104","moa":"Complement pathway","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aviceda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aviceda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Aviceda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AVD-104","moa":"Complement pathway","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aviceda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aviceda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Aviceda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kedrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Human Plasminogen","moa":"Fibrinogen","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kedrion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Kedrion \/ Undisclosed"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Betamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Betamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"London Health Sciences Centre","sponsor":"Physician Services Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Corticosteroid","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"London Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London Health Sciences Centre \/ Physician Services Incorporated","highestDevelopmentStatusID":"9","companyTruncated":"London Health Sciences Centre \/ Physician Services Incorporated"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2013","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Johns Hopkins University \/ Allergan","highestDevelopmentStatusID":"9","companyTruncated":"Johns Hopkins University \/ Allergan"},{"orgOrder":0,"company":"Duke University","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Duke University \/ Ocular Therapeutix","highestDevelopmentStatusID":"9","companyTruncated":"Duke University \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Retina Specialists","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Retina Specialists","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Retina Specialists \/ Allergan","highestDevelopmentStatusID":"9","companyTruncated":"Retina Specialists \/ Allergan"},{"orgOrder":0,"company":"Gene Signal SAS","sponsor":"Johannes Gutenberg University Mainz | University Hospital of Cologne | Moorfields Eye Hospital NHS Foundation Trust","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Oligonucleotide","year":"2016","type":"Inapplicable","leadProduct":"Aganirsen","moa":"Insulin receptor substrate 1 mRNA","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Gene Signal SAS","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gene Signal SAS \/ Johannes Gutenberg University Mainz | University Hospital of Cologne | Moorfields Eye Hospital NHS Foundation Trust","highestDevelopmentStatusID":"9","companyTruncated":"Gene Signal SAS \/ Johannes Gutenberg University Mainz | University Hospital of Cologne | Moorfields Eye Hospital NHS Foundation Trust"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Undisclosed"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"University of New South Wales","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AZR-MD-001","moa":"Mitosis","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azura Ophthalmics \/ University of New South Wales","highestDevelopmentStatusID":"9","companyTruncated":"Azura Ophthalmics \/ University of New South Wales"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"Syneos Health | Cliantha Research","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"AZR-MD-001","moa":"Mitosis","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azura Ophthalmics \/ Syneos Health | Cliantha Research","highestDevelopmentStatusID":"9","companyTruncated":"Azura Ophthalmics \/ Syneos Health | Cliantha Research"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"University of New South Wales","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"AZR-MD-001","moa":"Mitosis","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azura Ophthalmics \/ University of New South Wales","highestDevelopmentStatusID":"9","companyTruncated":"Azura Ophthalmics \/ University of New South Wales"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"Avania","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AZR-MD-001","moa":"Mitosis","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azura Ophthalmics \/ Avania","highestDevelopmentStatusID":"9","companyTruncated":"Azura Ophthalmics \/ Avania"},{"orgOrder":0,"company":"Physician Recommended Nutriceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Physician Recommended Nutriceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Physician Recommended Nutriceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Physician Recommended Nutriceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Physician Recommended Nutriceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Physician Recommended Nutriceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Physician Recommended Nutriceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Physician Recommended Nutriceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Glaukos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Travoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Glaukos \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Glaukos \/ Undisclosed"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"CUREator","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"Selenium Sulfide","moa":"quaternary ammonium derivatives","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azura Ophthalmics \/ CUREator","highestDevelopmentStatusID":"9","companyTruncated":"Azura Ophthalmics \/ CUREator"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Selenium Sulfide","moa":"quaternary ammonium derivatives","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azura Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Azura Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Selenium Sulfide","moa":"quaternary ammonium derivatives","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azura Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Azura Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Selenium Sulfide","moa":"quaternary ammonium derivatives","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azura Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Azura Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"Selenium Sulfide","moa":"quaternary ammonium derivatives","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0.02,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Ointment","sponsorNew":"Azura Ophthalmics \/ OrbiMed Advisors","highestDevelopmentStatusID":"9","companyTruncated":"Azura Ophthalmics \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Selenium Sulfide","moa":"quaternary ammonium derivatives","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azura Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Azura Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"ACU-4429","moa":"Retinoid isomerohydrolase","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Kubota Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kubota Pharmaceutical \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"Kubota Pharmaceutical \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Price Vision Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Netarsudil","moa":"Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Price Vision Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Price Vision Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Price Vision Group \/ Undisclosed"},{"orgOrder":0,"company":"Price Vision Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Netarsudil","moa":"Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Price Vision Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Price Vision Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Price Vision Group \/ Undisclosed"},{"orgOrder":0,"company":"Price Vision Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2019","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Price Vision Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Price Vision Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Price Vision Group \/ Undisclosed"},{"orgOrder":0,"company":"Price Vision Group","sponsor":"Cornea Research Foundation of America","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Price Vision Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Price Vision Group \/ Cornea Research Foundation of America","highestDevelopmentStatusID":"9","companyTruncated":"Price Vision Group \/ Cornea Research Foundation of America"},{"orgOrder":0,"company":"Price Vision Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Price Vision Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Price Vision Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Price Vision Group \/ Undisclosed"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Serine\/threonine protein phosphatase 2B catalytic subunit, alpha isoform","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aurinia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Aurinia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Serine\/threonine protein phosphatase 2B catalytic subunit, alpha isoform","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aurinia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Aurinia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Serine\/threonine protein phosphatase 2B catalytic subunit, alpha isoform","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aurinia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Aurinia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Serine\/threonine protein phosphatase 2B catalytic subunit, alpha isoform","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aurinia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Aurinia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Serine\/threonine protein phosphatase 2B catalytic subunit, alpha isoform","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aurinia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Aurinia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Smith-Kettlewell Eye Research Institute","sponsor":"Eidactics | Sutter Health | Strabismus Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Smith-Kettlewell Eye Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Smith-Kettlewell Eye Research Institute \/ Eidactics | Sutter Health | Strabismus Research Foundation","highestDevelopmentStatusID":"9","companyTruncated":"Smith-Kettlewell Eye Research Institute \/ Eidactics | Sutter Health | Strabismus Research Foundation"},{"orgOrder":0,"company":"BCN Peptides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Somatostatin","moa":"Somatostatin receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"BCN Peptides","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BCN Peptides \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"BCN Peptides \/ Undisclosed"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Abbott Laboratories","highestDevelopmentStatusID":"9","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Abbott Laboratories"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Yangtze River-CMB International Industry Fund","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Series C Financing","leadProduct":"Esonadogene Imvoparvovec","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Neurophth Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Neurophth Therapeutics \/ Yangtze River-CMB International Industry Fund","highestDevelopmentStatusID":"9","companyTruncated":"Neurophth Therapeutics \/ Yangtze River-CMB International Industry Fund"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Esonadogene Imvoparvovec","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Neurophth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neurophth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Neurophth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EYE103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"EYE103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EYE103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"MacuCLEAR","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Hydralazine Hydrochloride","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"MacuCLEAR","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"MacuCLEAR \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"MacuCLEAR \/ Undisclosed"},{"orgOrder":0,"company":"MacuCLEAR","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Hydralazine Hydrochloride","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"MacuCLEAR","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacuCLEAR \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"MacuCLEAR \/ Undisclosed"},{"orgOrder":0,"company":"MacuCLEAR","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Hydralazine Hydrochloride","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"MacuCLEAR","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacuCLEAR \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"MacuCLEAR \/ Undisclosed"},{"orgOrder":0,"company":"Kukje Pharma","sponsor":"Samil Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"KSR-001-02","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Kukje Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kukje Pharma \/ Samil Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"Kukje Pharma \/ Samil Pharmaceutical"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"NR082","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Neurophth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neurophth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Neurophth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"NR082","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Neurophth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neurophth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Neurophth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"OC-01","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Oyster Point Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"OC-01","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Oyster Point Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"rAAV2-ND4","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Neurophth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neurophth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Neurophth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"rAAV2-ND4","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Neurophth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neurophth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Neurophth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"rAAV2-ND4","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Neurophth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neurophth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Neurophth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Topivert Pharma Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"TOP1630","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Topivert Pharma Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Topivert Pharma Ltd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Topivert Pharma Ltd \/ Undisclosed"},{"orgOrder":0,"company":"East Florida Eye Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"East Florida Eye Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"East Florida Eye Institute \/ Genentech","highestDevelopmentStatusID":"9","companyTruncated":"East Florida Eye Institute \/ Genentech"},{"orgOrder":0,"company":"Ophthalmic Consultants of Long Island","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Ophthalmic Consultants of Long Island","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ophthalmic Consultants of Long Island \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Ophthalmic Consultants of Long Island \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"MW02","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Kodiak Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody-biopolymer Conjugate","year":"2020","type":"Agreement","leadProduct":"Tarcocimab Tedromer","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lonza Biologics Inc \/ Kodiak Sciences","highestDevelopmentStatusID":"9","companyTruncated":"Lonza Biologics Inc \/ Kodiak Sciences"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Silkiss Eye Surgery","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GW Pharmaceutical \/ Silkiss Eye Surgery","highestDevelopmentStatusID":"9","companyTruncated":"GW Pharmaceutical \/ Silkiss Eye Surgery"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Ă—
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target